Transplanted epithelial stem cells from a healthy eye repaired irreversible corneal injury and restored at least partial ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an ...

In December, the Global Fund and the US President’s Emergency Plan for Aids Relief committed to funding the roll-out of ...

From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to ...

Under U.S. law, most patents are limited to a term of 20 years from the earliest nonprovisional filing date. However, Patent Term Adjustment (PTA) ...

Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...

Vivani Medical Cofounder and CEO Adam Mendelsohn, Ph.D. discusses the company’s first application of the NanoPortal, ...

With over seven years of experience in data science and analytics, Nidhi has led high-impact projects at leading healthcare ...